HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Ovid Therapeutics (NASDAQ:OVID) and maintained a price target of $3.
August 19, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Ovid Therapeutics and maintained a price target of $3.
The reiteration of a Buy rating and the maintenance of a $3 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100